English  |  正體中文  |  简体中文  |  Total items :2853327  
Visitors :  44989440    Online Users :  1665
Project Commissioned by the Ministry of Education
Project Executed by National Taiwan University Library
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
About TAIR

Browse By

News

Copyright

Related Links

"thongprasert s"

Return to Browse by Author
Sorting by Title Sort by Date

Showing items 1-10 of 23  (3 Page(s) Totally)
1 2 3 > >>
View [10|25|50] records per page

Institution Date Title Author
臺大學術典藏 2022-06-27T07:02:01Z Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): A randomised, double-blind trial Wu Y.-L.; Lee J.S.; Thongprasert S.; CHONG-JEN YU; Zhang L.; Ladrera G.; Srimuninnimit V.; Sriuranpong V.; Sandoval-Tan J.; Zhu Y.; Liao M.; Zhou C.; Pan H.; Lee V.; Chen Y.-M.; Sun Y.; Margono B.; Fuerte F.; Chang G.-C.; Seetalarom K.; Wang J.; Cheng A.; Syahruddin E.; Qian X.; Ho J.; Kurnianda J.; Liu H.E.; Jin K.; Truman M.; Bara I.; Mok T.
臺大學術典藏 2022-06-27T07:01:34Z Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC Patients treated with first-line intercalated erlotinib and chemotherapy Mok T.; Wu Y.-L.; Lee J.S.; CHONG-JEN YU; Sriuranpong V.; Sandoval-Tan J.; Ladrera G.; Thongprasert S.; Srimuninnimit V.; Liao M.; Zhu Y.; Zhou C.; Fuerte F.; Margono B.; Wen W.; Tsai J.; Truman M.; Klughammer B.; Shames D.S.; Wu L.
臺大學術典藏 2022-06-27T07:00:18Z Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer Mok T.; Ladrera G.; Srimuninnimit V.; Sriuranpong V.; CHONG-JEN YU; Thongprasert S.; Sandoval-Tan J.; Lee J.S.; Fuerte F.; Shames D.S.; Klughammer B.; Truman M.; Perez-Moreno P.; Wu Y.-L.
臺大學術典藏 2022-05-10T08:10:07Z Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival Lee C.K.; Davies L.; Wu Y.-L.; Mitsudomi T.; Inoue A.; Rosell R.; Zhou C.; Nakagawa K.; Thongprasert S.; Fukuoka M.; Lord S.; Marschner I.; YU-KANG TU; Gralla R.J.; Gebski V.; Mok T.; Yang J.C.-H.
臺大學術典藏 2021-08-31T06:29:46Z Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma ANN-LII CHENG; Thongprasert S.; Lim H.Y.; Sukeepaisarnjaroen W.; Yang T.-S.; Wu C.-C.; Chao Y.; Chan S.L.; Kudo M.; Ikeda M.; Kang Y.-K.; Pan H.; Numata K.; Han G.; Balsara B.; Zhang Y.; Rodriguez A.-M.; Zhang Y.; Wang Y.; Poon R.T.P.
臺大學術典藏 2020-12-02T02:33:44Z A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER) Shi Y.;Au J.S.-K.;Thongprasert S.;Srinivasan S.;Tsai C.-M.;Khoa M.T.;Heeroma K.;Itoh Y.;Cornelio G.;PAN-CHYR YANG; Shi Y.; Au J.S.-K.; Thongprasert S.; Srinivasan S.; Tsai C.-M.; Khoa M.T.; Heeroma K.; Itoh Y.; Cornelio G.; PAN-CHYR YANG
臺大學術典藏 2020-12-02T02:33:18Z The prevalence of expression of MAGE-A3 and PRAME tumor antigens in East and South East Asian non-small cell lung cancer patients Thongprasert S.; Pan-Chyr Yang; Lee J.S.; Soo R.; Gruselle O.; Myo A.; Louahed J.; Lehmann F.F.; Brichard V.G.; Coche T.; Thongprasert S.; PAN-CHYR YANG; Lee J.S.; Soo R.; Gruselle O.; Myo A.; Louahed J.; Lehmann F.F.; Brichard V.G.; Coche T.
臺大學術典藏 2020-08-13T06:33:55Z Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: A combined clinical-molecular pathological approach Lu S.; Thongprasert S.; Salto-Tellez M.; Tsao M.-S.; JIN-YUAN SHIH; Chang G.-C.; Au J.S.-K.; Chou T.-Y.; Lee J.-S.; Shi Y.-K.; Radzi A.; Kang J.-H.; Kim S.-W.; Tan S.-Y.; Yang J.C.-H.
臺大學術典藏 2020-08-12T06:34:46Z Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC Patients treated with first-line intercalated erlotinib and chemotherapy Mok T.;Wu Y.-L.;Lee J.S.;Chong-Jen Yu;Sriuranpong V.;Sandoval-Tan J.;Ladrera G.;Thongprasert S.;Srimuninnimit V.;Liao M.;Zhu Y.;Zhou C.;Fuerte F.;Margono B.;Wen W.;Tsai J.;Truman M.;Klughammer B.;Shames D.S.;Wu L.; Mok T.; Wu Y.-L.; Lee J.S.; CHONG-JEN YU; Sriuranpong V.; Sandoval-Tan J.; Ladrera G.; Thongprasert S.; Srimuninnimit V.; Liao M.; Zhu Y.; Zhou C.; Fuerte F.; Margono B.; Wen W.; Tsai J.; Truman M.; Klughammer B.; Shames D.S.; Wu L.
臺大學術典藏 2020-05-26T09:27:27Z Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: Subset analysis from the ISEL study Botwood N; Thatcher N.; Watkins C; Tsao C.-J; CHIH-HSIN YANG; Ganzon D; Perng R.-P; Tan E.H; Thongprasert S; Parikh P; Chang A; Chang A;Parikh P;Thongprasert S;Tan E.H;Perng R.-P;Ganzon D;Chih-Hsin Yang;Tsao C.-J;Watkins C;Botwood N;Thatcher N.

Showing items 1-10 of 23  (3 Page(s) Totally)
1 2 3 > >>
View [10|25|50] records per page